하이로닉 인터내셔널 웹사이트로 이동합니다.
인터내셔널 웹사이트에는 수출용 제품으로 대한민국에서 허가하지 않은 장비 및 서비스 내용을 포함하고 있습니다. 해당 내용은 대한민국의 의료기기 광고 심의, 규제를 받지 않습니다.
It goes to the HIRONIC INTL. website.
The Intrrnation Web Site contains equipment and services that are not authorized by the Republic of Korea These contents are not subject to review and regulation of medical devices in Korea.
하이로닉 US 웹사이트로 이동합니다.
US 웹사이트의 내용은 "FDA"로 부터 허가승인된 품목의 제품 정보에 관한 것으로, 대한민국의 소비자 보호를 위한 국내법 의료기기의 광고 심의, 규제를 받지 않습니다.
It goes to the HIRONIC US website.
The contents of the US web page are about product information of items approved for "FDA". They are not subject to advertising deliberation and regulation of domestic law medical devices for consumer protection in Korea.
하이로닉 EU 웹사이트로 이동합니다.
EU 웹사이트의 내용은 "CE MDD 또는 CE MDR"로 부터 허가승인된 품목의 제품 정보에 관한 것으로, 대한민국의 소비자 보호를 위한 국내법 의료기기의 광고 심의, 규제를 받지 않습니다.
It goes to the HIRONIC EU website.
The contents of the EU(European) web page are about product information of items approved for "CEMDD or CEMDR" in EU countries. They are not subject to advertising deliberation and regulation of domestic law medical devices for consumer protection in Korea.
Hironic (CEO Jin-Woo Lee, www.hironic.com), a leading innovator of medical aesthetic laser and energy devices, announced today the launch of ‘JUVINA’ filler in order to penetrate the global facial aesthetics market. As an industry leader in medical aesthetics with a strong global network and customer base, Hironic now plans to expand its filler business through a strategic partnership with Pronexx.
Hironic’s business strategy is to rapidly gain the filler market share by utilizing its vast network of global distributors which already sell Hironic’s lineup of medical aesthetic devices. With Hironic’s recognition among skin and plastic surgery clinics worldwide, JUVINA is expected to contribute highly to Hironic’s short-term revenue growth this year.
JUVINA provides lift to the cheeks and volume to correct and smooth smile lines. JUVINA is safe to use because it is made up of Hyaluronic Acid (HA), a natural substance found in the human body. When injected, Hyaluronic Acid enhances the skin’s elasticity and ability to retain moisture. JUVINA is injected deep into the dermis, and patients can immediately feel the difference with a more youthful-looking experience. With Hironic’s proprietary filler technology, the results are natural and long lasting. For optimal treatment of each skin area, JUVINA collection of fillers comes in 6 different variations - 3 levels of intensity (Soft, Balance and Intense), with and without Lidocaine.
Hironic plans to launch JUVINA at the end of June and will focus on overseas market development in the early stages. According to industry sources, the global facial aesthetics market is expected to grow at a CAGR of 11.6% until 2020. The dermal filler market is expected to grow 13% annually and reach $2.7 billion by 2020. Furthermore, the Chinese market is expected to grow even more explosively at a CAGR of 30%, from $ 8.4 million in 2014 to $230 million by 2018.
“We, at Hironic, are excited to finally launch JUVINA filler which we have planned for several years. Hironic will continue to provide innovative products and services to our valued customers,” said CEO Jin-Woo Lee.
Established in 2007, Hironic is a leading innovator of medical aesthetic laser and energy devices. Committed to creating value for human beauty and health, Hironic provides a diverse range of medical aesthetic products which include DOUBLO™, a skin-lifting device utilizing HIFU (High Intensity Focused Ultrasonic) technology for skin rejuvenation, MICOOL™, which permanently destroys fat cells for body shaping using Cryo Fat Reduction technology, MIRACLEAR™ for acne treatment and EASYMO GRAFT™, a non-invasive hair transplant device for effective hair loss treatment.
